- Triveni Bio raises $65M ahead of upcoming readouts on eczema drugsTriveni Bio announced a $65 million Series C after its second asset for eczema entered clinical studies last month. The Series C was co-led by Ascenta Capital and Janus Henderson Investors and in…Endpoints · 1mo ago↗ source
- Migraine biotech Vedana Therapeutics makes its debut with $46M Series AVedana Therapeutics has emerged from stealth with $46 million in Series A proceeds with the goal of developing treatments that could free patients from migraines entirely. Available treatments fo…Endpoints · 1mo ago↗ source
- Opinion: As a physician, I have never been more concerned about rates of congenital syphilis“As a physician and former public health official, I have never been more concerned about those rates of congenital syphilis,” writes Jeffrey D. Klausner.